Khaled Musallam, Founding Director of Center for Research on Rare Blood Disorders (CR-RBD) at Burjeel Holdings, shared on their LinkedIn:
”Happy to share that abstracts presented during the WIN Symposium 2024 are now published in the Journal of Immunotherapy and Precision Oncology.”
Read further.
Source: Khaled Musallam/LinkedIn